Tirzepatide
Dual GIP and GLP-1 agonist. Beats Semaglutide head-to-head on weight loss and glycaemic control, and is becoming the default first-line choice when both are available.
Choose an option
- Pay with Bitcoin
- Discreet shipping within Germany
- Purity-guaranteed batches
- 14-day refund period if unsatisfied
Delivery & guarantee
Orders typically arrive within 3 weeks.
If your delivery arrives late, you'll receive a discount on your next order.
About
Tirzepatide pulls on two incretin levers at once: GLP-1 like Semaglutide, plus GIP, a second gut hormone that potentiates insulin release and modulates appetite through a different central pathway. The SURPASS programme (type 2 diabetes) and SURMOUNT programme (obesity) put it at the front of every comparison: ~21% body-weight loss at 15 mg over 72 weeks in SURMOUNT-1, vs the ~15% Semaglutide delivers at 2.
Read the full research guideWhy people choose it
- Average 20 to 22% body-weight reduction at the 15 mg dose over 72 weeks (SURMOUNT-1)
- Stronger HbA1c reduction than Semaglutide in head-to-head trials (SURPASS-2 showed roughly 0.5 percentage points more)
- Powerful blunting of hedonic food cravings. Ultra-processed and high-fat items lose their pull most noticeably
- Often tolerated at maintenance by users who could not stay on escalated Semaglutide
At a glance
- Experience level
- Beginner-friendly
- Administration
- Subcutaneous
Sold for laboratory research only. Not for human consumption. No therapeutic claims are made.
Sign in to view this product
Tirzepatide
Log in or create a free account to see full details and prices.
Don't have an account? Sign up